Tregzi is the second cell therapy to be approved by the FDA for use in the context of managing GVHD in HSCT patients, albeit ...

When it comes to global pharma pricing and market access, this moment is one of unprecedented change. As policy initiatives like Most Favoured Nations (MFN) and the EU’s Joint Clinical Assessment ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

The Memo deal falls into the latter camp, as while the BK polyomavirus is common, it usually remains inactive in the body and only causes problems in people with a weakened immune system, including ...

Women with polyendocrine metabolic ovarian syndrome (PMOS) in the UK should get diagnosed sooner and be offered an annual review of their condition, according to new guidance from NICE. Draft guidance ...

Digital and clinical trial tech firms expand commercial and operational leadership. Digital health and technology-enabled service providers also made some key hires. AES Cleanroom Technology ...

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder (SAD), cratering ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...

Eli Lilly, Regeneron, and five other companies have been selected to take part in the FDA's PreCheck pilot programme, designed to make it easier and quicker to set up US manufacturing facilities. The ...

In a second M&A announcement today, Zymeworks has reached an agreement to buy Theravance Biopharma, claiming rights to ...